产品名称
黄嘌呤, BioUltra, ≥99%
生物来源
synthetic (organic)
质量水平
产品线
BioUltra
方案
≥99%
表单
powder
杂质
≤0.0005% Phosphorus (P)
≤0.1% Insoluble matter
灼烧残渣
≤0.1%
溶解性
1 M NaOH: 0.1 M, clear, colorless to light yellow
痕量阴离子
sulfate (SO42-): <0.05%
痕量阳离子
Al: ≤0.0005%
Ca: ≤0.0005%
Cu: ≤0.0005%
Fe: ≤0.0005%
K: ≤0.005%
Mg: ≤0.0005%
NH4+: ≤0.05%
Na: ≤0.005%
Pb: ≤0.001%
Zn: ≤0.0005%
SMILES字符串
O=C1NC(=O)c2nc[nH]c2N1
InChI
1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)
InChI key
LRFVTYWOQMYALW-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
黄嘌呤及其衍生物天然存在于动物器官、酵母、土豆、咖啡豆和茶叶中。
黄嘌呤是一种嘌呤,可经由嘌呤代谢途径通过不同前体生成:
- 鸟嘌呤脱氨酶催化的鸟嘌呤脱氨
- 黄嘌呤氧化还原酶催化的次黄嘌呤转化
应用
本品(黄嘌呤)可作为底物测定黄嘌呤氧化酶(XOD)的抑制性。还可用于:
- 酵母培养
- 人类细胞系培养
- 重组病毒克隆为大肠杆菌中的BAC(细菌人工染色体)
生化/生理作用
黄嘌呤和黄嘌呤氧化酶可用于生成超氧自由基,测定超氧化物歧化酶的活性。
特点和优势
- 用于测定痕量金属含量(详情参见性质栏和技术规格说明书)
- 用于测定硫酸盐含量(详情参见性质栏和技术规格说明书)
储存分类代码
11 - Combustible Solids
WGK
WGK 3
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Optimization of total phenolic contents, antioxidant, and in-vitro xanthine oxidase inhibitory activity of sunflower head
Mehmood A, et al.
CYTA-journal of Food, 16, 957-964 null
Insights from multispectral and molecular docking investigation on the xanthine oxidase inhibition by 1, 4-dicaffeoylquinic acid
Cao W, et al.
Journal of Molecular Structure, 1219, 128475-128475 null
Resistance of postharvest biocontrol yeasts to oxidative stress: a possible new mechanism of action.
Raffaello Castoria et al.
Phytopathology, 93(5), 564-572 (2008-10-24)
ABSTRACT We detected the generation of the reactive oxygen species (ROS) superoxide anion ( O.(-) (2)) and hydrogen peroxide (H(2)O(2)) in apple wounds 2 immediately after wounding, and assessed the relationships between (i) timely colonization of apple wounds by biocontrol
Ken Okamoto et al.
Current pharmaceutical design, 19(14), 2606-2614 (2012-11-03)
Xanthine oxidoreductase (XOR), a complex flavoprotein, catalyzes the metabolic reactions leading from hypoxanthine to xanthine and from xanthine to urate, and both reactions take place at the molybdenum cofactor. The enzyme is a target of drugs for therapy of gout
Carolyn F Deacon et al.
Expert opinion on investigational drugs, 19(1), 133-140 (2009-12-02)
Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects. Preclinical and clinical studies of linagliptin, a new oral antidiabetic agent, including data presented at Scientific
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持